UK - Schroders Ventures Life Sciences exits PowerMed via sale to Pfizer

Pfizer Inc has announced it has entered into an agreement to acquire PowderMed Ltd, an Oxford-based company specializing in the emerging science of DNA-based vaccines. PowderMed has developed a unique and proprietary technology to deliver DNA directly to the cells of the bodyт€™s immune system and is advancing a promising pipeline of proprietary vaccine candidates for influenza and chronic viral diseases.